Genprex -- Immunogene Therapy VS NSCLC

Warning value reached over +1000% in 2 months
99% will be relapsed!
S F  

5,000,000  Mill. shares of common stock, par value $0.001 per share,
at an offering price of $3.50 per share.
S F  

Wie in #12/#14 schon vermutet, nimmt Genprex jetzt mal einen größeren Schluck aus der Pulle

• Offering 5 Mio. neue Aktien zu je 3,50$ ~ 17,5 Mio. $ Erlös
  

https://seekingalpha.com/news/...1-genprex-down-17-on-equity-offering

 

wie stuft ihr genprex zukunft bezogen auf 2020 ein ?  

Buy: $1,66  
Sell: $3,66 (automatic)
Vol.: 466K
Profit: +120%
First: $1,60
High: $3,80
S F    

 

 

Zweite Fast Track Zulassung für Genprex. Nach 190% gestern dürfte das erstmal ein Multi-Day Runner werden. 

https://finance.yahoo.com/news/...ancer-program-scores-142122426.html

 

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes 

AUSTIN, Texas — (January 4, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex’s gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

“ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community. The data further support the potential of Genprex’s novel gene therapy being developed for the treatment of Type 1 diabetes to change the trajectory of this devastating disease,” said Mark Berger, MD, Genprex’s Chief Medical Officer. “Using the expression of Pdx1 and MafA transcription factors, this approach has been shown first in mice and then in non human primate studies to lead to the creation of new beta-like cells that produce insulin and may provide long-term replacement of beta-cells.”

The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas. In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that using a similar approach the exhausted beta cells will be rejuvenated and replenished.  

Presentation Details:

Abstract Number: 203

Abstract Title: Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non-Human Primates in a Toxin-Induced Diabetes Model

Format: Oral Presentation

Presenter: Ranjeet Kalsi, DO, representing the laboratory of  George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery, University of Pittsburgh School of Medicine

Time/Date: 1:45 pm Central European Standard Time on Saturday, February 25, 2023

https://www.genprex.com/news/...technologies-treatments-for-diabetes/